Compounds / Metabolic / Adipotide

Adipotide

Adipotide (Prohibitin-TP01) — Prohibitin-Targeting Peptidomimetic
MetabolicEmerging ResearchFDA: Not approved; Phase 1 halted

Overview

⚠ CAUTION: Phase 1 trial discontinued due to serious safety concerns (renal toxicity). Notable weight loss in obese rodents and primates preclinically. Clinical development halted.

Mechanism of Action

Targets prohibitin on blood vessels within white adipose tissue. Delivers pro-apoptotic sequence destroying those vessels, causing fat cell death by cutting off blood supply. Unique targeted anti-adiposity mechanism.

Molecular Profile

Molecular weight
~2.6 kDa
CAS number
Not assigned

Key Research Findings

Prohibitin targeting; fat vasculature destruction; notable preclinical weight loss; Phase 1 halted for safety.

Published Research

Nature Medicine (2004)
Kolonin MG et al. Reversal of obesity by targeted ablation of adipose tissue
View source

Related Metabolic Compounds

SemaglutideTirzepatideRetatrutideCagrilintideMazdutideBioglutide
Clinical Guidance

Research data is not a treatment plan. If you are considering Adipotide, the questions that matter are whether it suits your history, your labs and your goals. That is a conversation with a licensed physician, not a lookup.

Speak with a physician LATOM Wellness is a physician-led telehealth practice. Consultation only. No compound is sold on this site.
Running Adipotide? Log doses and track your cycle.

Interactive tools for this compound:

Reconstitution calculator  ·  Full deep dive  ·  Peptide fundamentals